



**FOR IMMEDIATE RELEASE**

July 25, 2007

Contact: Larry J. Lapila  
VP, Business Development  
[llapila@bpirx.com](mailto:llapila@bpirx.com)

**Breckenridge Pharmaceutical has entered into an agreement with Midland HealthCare LLC to develop and market generic liquid ANDA.**

Boca Raton, Florida– Breckenridge has entered into an agreement with Midland HealthCare LLC, Kansas City, KS. to develop and manufacture a liquid generic ANDA product. Breckenridge plans to file an ANDA with the FDA in late 2007. Upon approval by the FDA, Midland will manufacture and Breckenridge will market and distribute the product on an exclusive basis.

Breckenridge has an aggressive Product Development program and looks forward to adding more products to its ANDA portfolio during 2007 and 2008.

**About Breckenridge:**

Breckenridge Pharmaceutical is a privately held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of ValuBrand™ and Generic prescription products in many therapeutic categories. The Breckenridge label is widely accepted in over 100 accounts including Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets 100 products, more than 150 sku's, in most dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions and Topicals.

**About Midland:**

Midland HealthCare LLC and its affiliated company, Midland Pharmaceutical LLC were established by the ex-Presidents of two established generic pharmaceutical manufacturing and marketing companies. The Midland companies commenced operations in 2005 and are located in Kansas City on their own 35 acre campus equipped to manufacture high quality prescription liquid solution, suspension, tablet and capsule products. Midland HealthCare markets its own products through all marketing channels and also collaborates with other established pharmaceutical companies to develop and manufacture products for marketing by such partners.

For Further Information, please contact:

**Breckenridge Pharmaceutical**

Larry Lapila, Vice President Business Development  
TEL: 860-828-8140 FAX: 860-828-8142  
e-Mail: [llapila@bpirx.com](mailto:llapila@bpirx.com)

**Midland HealthCare LLC**

Raman Kapur, Chairman & CEO  
609-933-1492 Fax: 609-452-2777  
e-mail: [ram.kapur@patmedia.net](mailto:ram.kapur@patmedia.net)